Actimed Therapeutics Limited

Psioxus Therapeutics Limited

CharitÉ—universitaetsmedizn Berlin

Charité – Universitätsmedizin Berlin

Par Pharmaceuticals, Inc.

Coats, Andrew J.s.

Jochen Springer

Stefan Anker

Andrew J S Coats

Andrew Js Coats

John William Beadle

Andrew Coats

Andrew JS Coats

The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.

S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis

The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.

Oxprenolol compositions for treating cancer

The present invention is directed to selective AT2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.

Selective AT2 receptor agonists for use in treatment of cachexia

The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.

Prevention and treatment of sarcopenia

Growing community of inventors

Falkensee, Germany

Jochen Springer